These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 38198112)

  • 1. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
    Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
    Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Dixon-Douglas J; Loi S
    Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
    O'Rourke H; Hart C; De Boer RH
    Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials of immunotherapy in triple-negative breast cancer.
    Howard FM; Pearson AT; Nanda R
    Breast Cancer Res Treat; 2022 Aug; 195(1):1-15. PubMed ID: 35834065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
    Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
    Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J
    BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
    Desai NV; Tan AR
    JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy and breast cancer: an overview.
    Mezni E; Behi K; Gonçalves A
    Curr Opin Oncol; 2022 Sep; 34(5):587-594. PubMed ID: 35838204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?
    Giugliano F; Valenza C; Tarantino P; Curigliano G
    Expert Opin Investig Drugs; 2022 Aug; 31(8):855-874. PubMed ID: 35762248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Mohamed A; Kruse M; Tran J
    Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
    Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immune checkpoint inhibition in triple negative breast cancer.
    Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
    Expert Rev Anticancer Ther; 2023; 23(10):1095-1106. PubMed ID: 37771270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.
    De Santis P; Perrone M; Guarini C; Santoro AN; Laface C; Carrozzo D; Oliva GR; Fedele P
    Explor Target Antitumor Ther; 2024; 5(1):232-250. PubMed ID: 38464390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.